cagrilintide novo nordisk Nordisk's next-gen obesity drug CagriSema trial results disappoint investors Novo Nordisk flags Cagrilintide promise
Novo Nordisk flags Cagrilintide promise in hunt for next obesity drug Novo Nordisk's next generation weight loss drug CagriSema matches Lilly's Zepbound in major trial, but doesn't surpass it CNN No change' for CagriSema as Novo ditches single chamber device Novo's Amylin Injectable Cagrilintide Hits 11.8% Weight Reduction in Phase III Trial BioSpace Novo Nordisk Stock Rises on Trial Results for Cagrilintide Obesity Treatment
Pay in 4 interest-free payments of $6.44 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12




:max_bytes(150000):strip_icc()/GettyImages-2197227432-6dabff12e088403c8032fbae8a53811d.jpg)